Skip Navigation

European Heart Journal 2003 24(15):1383-1384; doi:10.1016/S0195-668X(03)00281-1
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Niemelä, K.
Right arrow Articles by Vikman, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niemelä, K.
Right arrow Articles by Vikman, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Early invasive therapy of non ST-elevation acute coronary syndromes — combined with upstream antiplatelet therapy: yes — but how early?

Kari Niemelä* and Saila Vikman

Division of Cardiology, Department of Internal Medicine, Tampere University Hospital, PL 2000, FI-33521, Tampere, Finland

* Correspondence to: Kari Niemelä. Tel. +358-3-2474312; fax +358-3-2474157
E-mail address: kari.niemela@pshp.fi

Received 19 May 2003; revised 19 May 2003; accepted 21 May 2003

The first 10% of the full text of this article appears below.

See doi:10.1016/S1095-668X(03)00259-8for the article to which this editorial refers

The increasing number of patients with non ST-elevation acute coronary syndromes (ACS) is placing an enormous economic burden on health care in Western countries. Recently updated European and American guidelines have clarified the recommendations for how these patients should be treated.1,2The well-conducted FRISC II trial strongly suggested the superiority of early invasive strategy compared to a more watchful ‘wait-and-see’ conservative strategy.3These observations were further confirmed by the TACTICS–TIMI 18 trial,4where early invasive strategy with an adjunctive upstream glycoprotein (GP) 2b/3a inhibitor from 4 to 48h (median 22h) before the intervention appeared to result in . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study: 2b/3a upstream therapy and acute coronary syndromes
Arnoud W. J. van ’t Hof, Suzanna T. de Vries, Jan-Henk E. Dambrink, Kor Miedema, Harry Suryapranata, Jan C. A. Hoorntje, A.T. Marcel Gosselink, Felix Zijlstra, and Menko-Jan de Boer
EHJ 2003 24: 1401-1405. [Abstract] [Full Text]